

Table 4. Interpretive breakpoints for antifungal susceptibility testing

Antifungal Agent	Fluconazole	Itraconazole	Voriconazole*	Flucytosine
Susceptible (S)	≤ 8	≤ 0.125	≤ 1	≤ 4
Susceptible-dose dependent (S-DD)	16-32	0.25 - 0.5	2	
Intermediate (I)				8-16
Resistant (R)	≥ 64	≥ 1	≥ 4	≥ 32
<i>C. albicans</i>	S	S	S	S
<i>C. tropicalis</i>	S	S	S	S
<i>C. parapsilosis</i>	S	S	S	S
<i>C. glabrata</i>	S-DD to R	S-DD to R	S-DD to R	S
<i>C. krusei</i>	R	R	S	R
<i>C. lusitaniae</i>	S	S	S	S

Shown are the breakpoints in µg/mL for *Candida* isolates against the indicated antifungal agents (386). A disk diffusion-based testing methodology is also available and provides comparable interpretive categories (388). See text for a discussion of the S-DD and I categories. Below this is shown the most common interpretive categories for isolates of the most common species of *Candida*. *The voriconazole interpretive breakpoints were approved by the National Committee for Clinical Laboratory Standards in January 2005 and are tentative during a one-year commentary period. Final breakpoints for this compound are expected January 2006.